Skip to main content

Latest stock market podcasts

From the helm: Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer

Bell Direct
February 5, 2021

In this instalment of our From the helm series, Bell Direct’s Jessica Amir speaks to Cyclopharm’s (ASX:CYC) MD & CEO, James McBrayer.

Cyclopharm is a little known Aussie company. Its medical technology is used in 60 countries around the world to help doctors identify lung capacity, as well as find potential blood clots. With earnings mostly coming from Europe, CYC’s US journey gathers momentum with USFDA approval looming. The US is home to the world’s largest nuclear medicine market.

In this video James discusses:

  • (0:31) What CYC does & its “imminent” entry into the US
  • (1:11) Key catalysts to drive share price growth – (1:47) Commercialising the product in the US
  • (2:46) CYC’s product being endorsed to help fight COVID-19 in the US – (3:31) How the company has reduced its risks
  • (4:56) After a 110% rise in share price last year, what can investors expect for the year ahead?

Morning Bell 6 May

Bell Direct
May 6, 2020

Morning Bell 5 May

Bell Direct
May 5, 2020

Morning Bell 4 May

Bell Direct
May 4, 2020

Weekly Wrap 1 May

Bell Direct
May 1, 2020

Morning Bell 1 May

Bell Direct
May 1, 2020

April Monthly Overview

Bell Direct
April 30, 2020

The case for investing in Gold via ETFs

Bell Direct
April 30, 2020

Morning Bell 30 April

Bell Direct
April 30, 2020

Morning Bell 29 April

Bell Direct
April 29, 2020

Morning Bell 28 April

Bell Direct
April 28, 2020

Morning Bell 27 April

Bell Direct
April 27, 2020

Weekly Wrap 24 April

Bell Direct
April 24, 2020